ADVM240920C8000
- 0.50
- +0.45+900.00%
Adverum Biotechnologies Newsroom
Mizuho Securities Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating
Adverum Biotechnologies: A Strong Buy on Promising Gene Therapy Prospects and Financial Stability
Express News | Adverum Biotechnologies Inc : Mizuho Cuts Target Price to $20 From $22
Truist Adjusts Price Target on Adverum Biotechnologies to $40 From $60, Maintains Buy Rating
TD Cowen Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating
Express News | Adverum Biotechnologies Inc : Truist Securities Cuts Target Price to $40 From $60
Adverum Biotechnologies Price Target Maintained With a $30.00/Share by HC Wainwright & Co.
Adverum Biotechnologies Analyst Ratings
RBC Capital Maintains Adverum Biotechnologies(ADVM.US) With Hold Rating, Cuts Target Price to $12
Oppenheimer Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating, Raises Target Price to $28
A Quick Look at Today's Ratings for Adverum Biotechnologies(ADVM.US), With a Forecast Between $12 to $30
Adverum Biotechnologies (ADVM) Receives a Hold From RBC Capital
Analysts' Top Healthcare Picks: Adverum Biotechnologies (ADVM), Astria Therapeutics (ATXS)
Adverum Biotechnologies' Ixo-vec Shows Promise in Wet AMD Treatment: Analyst Reiterates Buy Rating and $30 Price Target
Express News | Adverum Biotechnologies Inc : RBC Cuts Target Price to $12 From $15
Buy Rating for Adverum Biotechnologies Based on Promising Ixo-Vec Therapy and Strategic Growth Opportunities
Express News | Adverum Biotechnologies Q2 2024 Adj EPS $(0.89) Beats $(1.47) Estimate
Adverum Biotechnologies | 10-Q: Q2 2024 Earnings Report
Express News | Adverum Biotechnologies Inc: Cash Expected to Fund Operations Into Late 2025
Express News | Adverum Biotechnologies Reports Second Quarter 2024 Financial Results and Provides Program and Corporate Highlights